Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 73Carcinoma, Hepatocellular 67Stomach Neoplasms 52Pancreatic Neoplasms 40Rectal Neoplasms 30Colonic Neoplasms 30Neoplasms 21Liver Neoplasms 20Esophageal Neoplasms 19Neoplasm Metastasis 16Cholangiocarcinoma 16Esophageal Squamous Cell Carcinoma 14Gallbladder Neoplasms 12Biliary Tract Neoplasms 12Lung Neoplasms 10Gastrointestinal Neoplasms 7Adenocarcinoma Of Esophagus 7Ovarian Neoplasms 6Prostatic Neoplasms 5Neoplasms by Site 5Bile Duct Neoplasms 5Adenocarcinoma 5Polyps 4Neoplasms by Histologic Type 4Melanoma 4Hematologic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Adenoma 4Recurrence 3

Interventions

Gemcitabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Camurati-Engelmann Syndrome × Gastrointestinal × Clear all
NCT04066491 2023-11-14

Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC

EMD Serono

Phase 2/3 Terminated
309 enrolled 17 charts
Gastrointestinal

Biliary Tract Neoplasms, Camurati-Engelmann Syndrome, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡